Tasaki, Mamoru
Yamashita, Midori
Arai, Yukinori
Nakamura, Takafumi
Nakao, Shinsuke http://orcid.org/0000-0002-7807-1269
Funding for this research was provided by:
Astellas Pharma Inc.
Article History
Received: 18 September 2020
Accepted: 14 April 2021
First Online: 28 April 2021
Declarations
:
: MT, MY, YA and SN are employees of Astellas Pharma Inc., Japan. TN and SN are inventors on a patent related to recombinant oncolytic vaccinia viruses that was submitted by Astellas Pharma and Tottori University (U.S. Patent Publication No. US 2017/0340687, published 30 November 2017). All other authors declare that they have no competing interests.
: Mice were handled in accordance with the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) guidelines, and under the approval of the Institutional Animal Care and Use Committee of Astellas Pharma Inc., Tsukuba Research Center. <i>Animal source</i>: Male C57BL/6 mice were purchased from Charles River Laboratories Japan, Inc. (Kanagawa, Japan). <i>Cell line authentication</i>: Rabbit kidney RK13 cells, human lung carcinoma A549 cells and murine Lewis lung carcinoma (LLC) cells were purchased from American Type Culture Collection (ATCC) who had authenticated them.